International Journal of Research in Engineering and Management Sciences (IJREMS)
E-ISSN: 3107-7439

Research Article
VOL.: 1, Issue: 7, December 2025

AI-Augmented Clinical Oncology: Transforming Personalized Cancer Care Through Digital Intelligence

*[1]Dr. Nalini Deshpande,[2]Dr. Saurabh Tomar

[1]Professor,Department of Hematology, KLE Medical College, Belagavi, India.

Nalinideshpande77@gmail.com

[2]Associate Professor,Department of Medical Oncology, KLE Medical College, Belagavi, India.

Saurabhtomar44@gmail.com

ABSTRACT:
Artificial intelligence (AI) is fundamentally transforming clinical oncology by augmenting medical expertise with advanced computational intelligence capable of integrating diverse biomedical information across the entire cancer care continuum. The convergence of machine learning, deep learning, foundation AI models, multimodal transformers, graph neural networks, large language models, and generative artificial intelligence has created powerful digital ecosystems that support cancer screening, diagnosis, prognostic prediction, biomarker discovery, therapeutic optimization, clinical decision support, and survivorship management. Unlike conventional healthcare systems that often analyze isolated clinical variables, AI-augmented oncology integrates radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable technologies, electronic health records, patient-reported outcomes, and real-world clinical data into comprehensive patient-specific computational representations. These intelligent systems enable adaptive precision medicine by continuously learning from evolving biomedical evidence and longitudinal patient trajectories. Emerging technologies such as digital twins, federated learning, reinforcement learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further expand the capabilities of computational oncology while supporting personalized therapeutic strategies and multidisciplinary clinical decision-making. Despite remarkable technological progress, important challenges remain regarding multimodal data harmonization, algorithmic transparency, interoperability, cybersecurity, regulatory validation, ethical governance, and equitable implementation. This review provides a comprehensive overview of AI-augmented clinical oncology, emphasizing technological foundations, clinical applications, implementation challenges, and future perspectives for transforming personalized cancer care through digital intelligence.[1]

Keyword:Artificial intelligence, Clinical oncology, Precision medicine, Foundation models, Digital health, Computational oncology, Personalized cancer care, Clinical decision support, Digital pathology, Multimodal learning.

Received Date: 5 December 2025; **Accepted Date:** 15 December 2025; **Published Date:** 20 December 2025.

1.Introduction

Cancer management has evolved dramatically over the past several decades through advances in molecular biology, targeted therapeutics, immunotherapy, precision medicine, and digital healthcare technologies. Nevertheless, clinical oncology remains challenged by the remarkable biological heterogeneity of malignant diseases, the complexity of multimodal diagnostic information, and the rapidly expanding volume of biomedical knowledge available to healthcare professionals.[2]

Modern oncology generates enormous quantities of heterogeneous data through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory investigations, wearable biosensors, electronic health records, patient-reported outcomes, and real-world evidence. While each modality contributes valuable clinical information, integrating these diverse datasets into coherent therapeutic strategies exceeds traditional analytical approaches.[3]

Artificial intelligence has emerged as a transformative technology capable of augmenting clinical expertise by integrating multimodal biomedical information into unified computational representations that support evidence-based precision medicine. Rather than replacing clinicians, AI functions as an intelligent partner that enhances diagnostic accuracy, therapeutic planning, workflow efficiency, and personalized patient care.[4]

The convergence of digital intelligence, multimodal foundation AI models, and clinical oncology is redefining personalized cancer care by enabling continuously adaptive, data-driven, and patient-centered healthcare ecosystems.[5]

2.Evolution of AI in Clinical Oncology

Early computational applications in oncology relied primarily on statistical models and rule-based decision-support systems designed to assist with isolated clinical tasks. Although these approaches demonstrated clinical utility, their predictive capabilities were limited by handcrafted features, restricted datasets, and relatively simple computational architectures.[6]

Machine learning subsequently introduced data-driven predictive modeling, while deep learning enabled automated extraction of hierarchical features from radiological images, digital pathology slides, genomic data, and electronic health records. These developments substantially improved cancer detection, classification, prognostic prediction, and therapeutic response modeling.

The emergence of foundation AI models has further transformed oncology by enabling generalized biomedical representation learning through self-supervised training on massive multimodal datasets. Large language models, multimodal transformers, graph neural networks, and generative AI now support sophisticated clinical reasoning across diverse oncology applications.

Today, AI-augmented clinical oncology represents the integration of computational intelligence with multidisciplinary medical practice throughout the cancer care continuum.[7]

3.Foundation AI Models and Digital Intelligence

Foundation AI models differ fundamentally from conventional machine learning systems because they acquire generalized biomedical knowledge from large-scale multimodal datasets before adaptation to specialized clinical tasks. Rather than learning isolated prediction problems, these models develop transferable computational representations applicable across diagnosis, prognosis, biomarker discovery, therapeutic optimization, and clinical decision support.[8]

Self-supervised learning enables discovery of latent biological relationships without requiring extensive manual annotation, while multimodal transformer architectures integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, physician documentation, and electronic health records into unified patient-specific embeddings.

Graph neural networks further strengthen computational reasoning by modeling relationships among molecular pathways, immune populations, imaging phenotypes, therapeutic targets, clinical variables, and longitudinal outcomes, enabling systems-level understanding of cancer biology and treatment response.[9]

4.Computational Architecture

Modern AI-augmented oncology platforms consist of interconnected computational layers responsible for multimodal data acquisition, preprocessing, representation learning, predictive analytics, adaptive clinical reasoning, and intelligent decision support.[10]

The acquisition layer continuously collects radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and longitudinal electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode unstructured clinical narratives using natural language processing, and synchronize temporal patient information.

Foundation AI models generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging

DOI: https://doi.org/10.65477/ijrems.v1.i7.13

characteristics, physiological status, and clinical trajectories. Cross-modal attention mechanisms and graph neural networks subsequently integrate these embeddings into comprehensive patient-centered computational representations supporting adaptive precision medicine.[11]

5.Artificial Intelligence in Cancer Diagnosis

Artificial intelligence has significantly enhanced cancer diagnosis by integrating multiple diagnostic modalities into comprehensive computational frameworks. Foundation AI models analyze radiological imaging, digital pathology, laboratory investigations, molecular diagnostics, and clinical documentation simultaneously, enabling more accurate and reproducible disease characterization than isolated analyses.[12]

Deep learning algorithms automatically identify malignant lesions, classify tumor subtypes, detect microscopic abnormalities, quantify tumor burden, evaluate lymph node involvement, and estimate metastatic dissemination. Integration of imaging with molecular biology further enables prediction of actionable biomarkers directly from routine diagnostic studies.

These intelligent diagnostic systems improve early cancer detection, reduce interobserver variability, accelerate clinical workflows, and strengthen multidisciplinary diagnostic decision-making.

6.Precision Therapeutics and Treatment Planning

Personalized therapeutic planning represents one of the most impactful applications of AI-augmented oncology. Foundation AI models integrate molecular biology, imaging phenotypes, digital pathology, laboratory biomarkers, medication history, physiological monitoring, and longitudinal clinical information into unified computational frameworks supporting individualized treatment recommendations.[13]

Artificial intelligence predicts responsiveness to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations while simultaneously estimating treatment-related toxicity, recurrence probability, progression-free survival, and overall survival.

Adaptive learning algorithms continuously update therapeutic recommendations using newly acquired patient information, enabling dynamic optimization of cancer treatment throughout the clinical journey.[14]

7.Digital Pathology, Radiology, and Multimodal Integration

Digital pathology and radiological imaging provide complementary biological information across microscopic and macroscopic scales. Foundation AI models integrate whole-slide pathology images with computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, laboratory biomarkers, and multi-omics datasets into comprehensive computational representations of tumor biology.[15]

Multimodal transformers and graph neural networks identify latent relationships among tissue architecture, imaging phenotypes, molecular alterations, immune infiltration, angiogenesis, and therapeutic response while improving biomarker discovery, prognostic prediction, and precision medicine.

These integrated diagnostic ecosystems strengthen computational oncology by connecting anatomical imaging with microscopic pathology and molecular biology within unified clinical intelligence platforms.[16]

8.Clinical Decision Support and Digital Workflows

AI-augmented oncology provides the computational foundation for intelligent clinical decision-support systems capable of integrating heterogeneous biomedical information throughout routine clinical practice. Radiological imaging, pathology reports, molecular diagnostics, laboratory investigations, physician documentation, medication history, wearable technologies, patient-reported outcomes, and evidence-based treatment guidelines are harmonized into unified digital environments supporting multidisciplinary oncology care.[17]

Interactive clinical dashboards generate individualized diagnostic summaries, prognostic estimates, biomarker analyses, therapeutic recommendations, toxicity predictions, recurrence probabilities, and adaptive treatment pathways while facilitating collaboration among oncologists, radiologists, pathologists, surgeons,

DOI: https://doi.org/10.65477/ijrems.v1.i7.13

pharmacists, molecular biologists, and data scientists.

These intelligent workflows improve healthcare efficiency, reduce fragmentation of clinical information, and promote evidence-based personalized cancer care while supporting continuous quality improvement throughout oncology practice.[18]

9.Real-Time Clinical Intelligence and Continuous Learning

One of the defining characteristics of AI-augmented clinical oncology is the transition from static decision-support systems toward continuously learning digital intelligence capable of adapting throughout the patient journey. Unlike conventional algorithms that remain unchanged after deployment, modern foundation AI models continuously integrate newly acquired radiological imaging, digital pathology, laboratory investigations, liquid biopsy, wearable physiological monitoring, electronic health records, and real-world clinical outcomes into evolving computational frameworks.[19]

Continuous learning enables artificial intelligence to update diagnostic predictions, therapeutic recommendations, recurrence estimates, toxicity assessments, and survival forecasts in response to changes in tumor biology and patient physiology. Reinforcement learning further strengthens adaptive clinical reasoning by optimizing therapeutic strategies based on observed treatment outcomes and accumulated clinical experience.

These continuously evolving computational ecosystems support real-time precision oncology while ensuring that clinical recommendations remain aligned with the latest biomedical evidence and patient-specific disease evolution.[20]

10.Digital Twins and Personalized Cancer Management

Digital twin technology has emerged as one of the most innovative applications of AI-augmented oncology by creating continuously synchronized virtual representations of individual patients. Foundation AI models integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable technologies, medication history, and longitudinal clinical outcomes into dynamic computational patient models.[21]

These virtual patients enable simulation of tumor evolution, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival under multiple therapeutic scenarios before clinical intervention. Clinicians can therefore evaluate alternative treatment strategies while minimizing uncertainty and optimizing individualized care.

Digital twins provide an increasingly comprehensive framework for adaptive precision medicine by continuously incorporating updated biomedical information throughout diagnosis, treatment, follow-up, and survivorship.

11.Artificial Intelligence for Patient Engagement and Digital Health

AI-augmented oncology extends beyond physician decision support by strengthening patient engagement through intelligent digital health technologies. Conversational AI systems, virtual assistants, mobile health applications, wearable biosensors, and remote monitoring platforms continuously collect patient-reported outcomes, symptom assessments, medication adherence, quality-of-life measures, and physiological data outside traditional clinical environments.[22]

Natural language processing enables automated interpretation of patient communication, whereas large language models provide personalized educational resources, appointment reminders, medication guidance, and supportive care recommendations. Artificial intelligence also identifies early warning signs of treatment-related complications, psychological distress, nutritional deficiencies, and functional decline, allowing timely intervention before serious clinical deterioration occurs.

These patient-centered digital ecosystems strengthen continuity of care while promoting shared decision-making and personalized survivorship management.

12.Multidisciplinary Oncology Through Intelligent Collaboration

Modern cancer care depends upon effective collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, genetic

DOI: https://doi.org/10.65477/ijrems.v1.i7.13

counselors, nurses, and allied healthcare professionals. AI-augmented oncology facilitates multidisciplinary care by integrating heterogeneous biomedical information into unified computational platforms accessible across clinical specialties.[23]

Foundation AI models synthesize imaging findings, histopathological interpretations, molecular diagnostics, laboratory investigations, treatment history, clinical guidelines, and current scientific literature into comprehensive patient-centered summaries supporting multidisciplinary tumor board discussions.

These intelligent collaborative environments reduce information fragmentation, improve communication among healthcare professionals, accelerate consensus decision-making, and strengthen evidence-based precision oncology.

13.Clinical Implementation and Healthcare Transformation

Successful implementation of AI-augmented oncology requires integration of intelligent computational systems into existing healthcare infrastructure without disrupting clinical workflows. Foundation AI models increasingly function as embedded components of electronic health record systems, radiology workstations, digital pathology platforms, laboratory information systems, and hospital decision-support environments.[24]

Automation of repetitive administrative tasks—including clinical documentation, report generation, coding, appointment coordination, treatment scheduling, and data retrieval—reduces clinician workload while allowing healthcare professionals to devote greater attention to direct patient care.

At the institutional level, AI supports quality improvement initiatives, resource allocation, operational efficiency, population health management, clinical trial recruitment, and healthcare planning, thereby strengthening both individual patient care and broader oncology service delivery.

14.Explainability, Ethics, and Regulatory Governance

Despite remarkable advances in artificial intelligence, successful clinical implementation depends upon transparency, interpretability, and clinician trust. Explainable artificial intelligence (XAI) enables healthcare professionals to understand computational reasoning through attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, and counterfactual explanations that identify the clinical, molecular, and imaging variables responsible for AI-generated recommendations.[25]

Clinical translation also requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, continuous monitoring for algorithmic bias, cybersecurity safeguards, external benchmarking, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible governance further requires protection of patient privacy, informed consent, equitable access, transparency, accountability, and ongoing post-dedeployment monitoring to ensure safe and ethical implementation across diverse healthcare systems.

15.Future Perspectives

Future AI-augmented oncology ecosystems will increasingly integrate multimodal foundation models, agentic artificial intelligence, large language models, federated learning, reinforcement learning, digital twins, spatial multi-omics, liquid biopsy, Internet of Medical Things (IoMT) technologies, quantum computing, cloud-native healthcare infrastructure, and autonomous clinical reasoning systems into comprehensive digital healthcare platforms.[26]

These next-generation systems will continuously integrate molecular biology, imaging, pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, and real-world clinical outcomes while autonomously coordinating diagnostic workflows, optimizing therapeutic strategies, generating personalized patient communication, supporting clinical research, and continuously synthesizing biomedical evidence.

Such intelligent digital ecosystems are expected to transform oncology from episodic disease management toward predictive, preventive, adaptive, and continuously personalized cancer care.

16.Discussion

AI-augmented clinical oncology represents a major paradigm shift in healthcare by combining physician expertise with advanced computational intelligence capable of integrating heterogeneous biomedical information across the entire cancer care continuum. Foundation AI models enable comprehensive multimodal reasoning that extends beyond isolated diagnostic or therapeutic tasks, supporting adaptive clinical decision-making, intelligent workflows, digital twins, patient engagement, multidisciplinary collaboration, and precision medicine.[27]

Applications spanning computational pathology, radiology, multi-omics integration, therapeutic optimization, digital health, clinical decision support, and continuous learning demonstrate the extraordinary potential of digital intelligence to improve both patient outcomes and healthcare efficiency. Nevertheless, successful implementation requires continued advances in explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand, AI-augmented oncology will become an increasingly indispensable component of routine cancer care worldwide.

17.Conclusion

Artificial intelligence is fundamentally redefining clinical oncology by augmenting medical expertise with intelligent computational systems capable of integrating radiological imaging, digital pathology, molecular biology, laboratory biomarkers, wearable technologies, electronic health records, and longitudinal clinical intelligence into unified patient-centered frameworks supporting personalized precision medicine.[28]

Advances in foundation AI models, transformer architectures, graph neural networks, multimodal learning, self-supervised learning, digital twins, federated learning, reinforcement learning, large language models, agentic AI, and generative artificial intelligence are expected to further strengthen digital oncology ecosystems, enabling increasingly accurate diagnosis, individualized therapeutic optimization, continuous disease monitoring, evidence-based clinical decision-making, and adaptive patient-centered care.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, and regulatory agencies will accelerate responsible implementation of AI-augmented clinical oncology. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, and establish a new era of intelligent, personalized, and digitally connected oncology worldwide.[30]

18.References

1.Synthia, F. et al. (2020) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

2.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7

3.Dr.Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14

4.Dr.Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31

5.Dr.Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

6.Dr.Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16

7.Dr.Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL Intelligence'DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33

8.Joshi, A. et al. (2023) 'Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis', npj Precision Oncology, 7(1), p. 28.

9.Huang, S.C. et al. (2020) 'Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review', npj Digital Medicine, 3(1), p. 136.

10.Dr.Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.

11.Dr.Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8

12.Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.

13.Lambin, P. et al. (2017) 'Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis', European Journal of Cancer, 48(4), pp. 441-446.

14.Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.

15.Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.

16.Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.

17.Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.

18.Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.

19.Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial, Nature, 616(7956), pp. 259-265.

20.Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.

21.Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.

22.Dr.Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-

December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4

23.Dr.Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7

24.Dr.Ohmini Krishnamurthy Rajendran (Author), ANALYSIS OF DNA-DAMAGE AND CANCER-RELATED GENE EXPRESSION FOLLOWING SPACE-RADIATION EXPOSURE USING NASA OPEN SCIENCE DATA, Vol. 11 No. 5s (2025), International Journal of Advances in Signal and Image Sciences (IJASIS), https://xlescience.org/index.php/IJASIS/article/view/2054, DOI: https://doi.org/10.29284/jqgs5s28

25.Dr.Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5

26.Dr.Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5

27.Dr.Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38

28.Dr.Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

29.Dr.Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

30.Dr.Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18